益气补肾颗粒治疗对微小残留白血病患者CD4<sup>+</sup>CD8<sup>high</sup> T淋巴细胞和自然杀伤细胞的影响

作者	单位
许勇钢	中国中医科学院西苑医院
麻柔	中国中医科学院西苑医院
杨晓红	中国中医科学院西苑医院
唐旭东	中国中医科学院西苑医院
孙淑贞	中国中医科学院西苑医院

摘要点击次数: 1909

全文下载次数: 781

中文摘要:

目的探讨益气补肾颗粒治疗后CD4+CD8highT淋巴细胞的变化及其对微小残留白血病(mini-mal residual leukemia,MRL)预后的意义。方法用多参数流式细胞技术比较分析36例MRL患者应用益气补肾颗粒治疗前后CD4+CD8 highT淋巴细胞亚群和自然杀伤细胞(NK细胞)改变。结果 (1)MRL患者3年持续完全缓解率、生存率分别为75.0%、80.5%,5年持续完全缓解率、生存率分别为63.9%、72.2%。(2)与治疗前比较,治疗后的MRL的CD4+CD8highT淋巴细胞百分率(%)和绝对值显著上升(P<0.01);(3)与治疗前比较,治疗后MRL的NK细胞百分率(%)和绝对值均显著上升(P<0.05,P<0.01)。结论益气补肾颗粒可能通过调节机体自身免疫功能,提高CD4+CD8highT和NK细胞的绝对数量,杀伤或抑制体内残存白血病细胞,延长MRL患者的无病生存期。

英文摘要:

Objective To explore the effect of Yiqi Bushen Granule (YBG) on CD4+CD8high T lymphocyte in patients with minimal residual leukemia (MRL) and to probe its prognosis after treatment. Methods The changes of CD4+CD8highT lymphocyte subgroup and natural killer (NK) cells in 36 patients (16 males and 20 females) received long-term (>3 months) YBG therapy before and after treatment were analyzed using multi-parameter flow cytometry and controlled by those in 34 healthy persons (19 males and 15 females). Results The 3-year and 5-year complete remission rates in MRL patients were 75.0% and 63.9%; their 3-year and 5-year survival rates were 80.5% and 72.2%,respectively; as compared with the baseline,the absolute value and percentage of CD4+CD8high T lymphocyte and NK cells were all significantly raised after treatment (P<0.05 or P<0.01). Conclusion YBG could prolong the disease-free survival in MRL patients by way of regulating the immune function of organism,elevating the amount of CD4+CD8high T lymphocyte and NK cells to kill or suppress the residual leukemic cell in body.

关闭